CH
NRXP icon

CVI Holdings’s NRX Pharmaceuticals NRXP Stock Holding History

CVI Holdings’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-48,357
Closed -$234K – 242
2023
Q2 		$234K Buy
+48,357
New +$291K 0.25% 52
2022
Q2 		– Sell
-62,598
Closed -$1.53M – 942
2022
Q1 		$1.53M Buy
+62,598
New +$2.04M 0.1% 310

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CVI Holdings's NRXP Position: Q3 2023 in Review

CVI Holdings sold out of NRX Pharmaceuticals (NRXP) in Q3 2023, closing a stake of 48,357 shares — an estimated $234K sold.

CVI Holdings first reported a position in NRXP in Q1 2022 and held it in 2 quarters. The position peaked at $1.53M in Q1 2022. 34 funds tracked by Wall St. Rank hold NRXP as of Q3 2023.

  • CVI Holdings reported no remaining NRX Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • CVI Holdings sold 48,357 NRX Pharmaceuticals shares in Q3 2023, an estimated $234K.
  • CVI Holdings first reported a position in NRX Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • CVI Holdings's NRX Pharmaceuticals position peaked at $1.53M in Q1 2022.
  • 34 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2023.

Based on CVI Holdings's 13F filing for Q3 2023, filed 14 Nov 2023.